Biotech Values

[DewDiligence]

Pro-ENTA—(facetious)—tweet re ALGS IPO:

So, $ENTA has $400+ million of net balance sheet cash, generates $200 mill/yr of royalty (i.e., cost free) revenue, and has a broader wholly owned pipeline with a proven history of bringing 2 blockbuster drugs to market, but has a market cap of $900 million. Makes total sense...

— Florida Hedgie (@FLHedgie) October 16, 2020